[The use of activated recombinant factor VII in the treatment of nasopharyngeal hemorrhage in a patient with extensive fronto-basal injuries. Case report].
The main indication for recombinant activated factor VII (rFVIIa) is the treatment of patients with hemophilia or other hemostatic disturbances. Additionally, rFVIIa has been considered as a universal hemostatic agent prompting its use in the management of severe uncontrolled bleeding in patients without pre-existing coagulopathies. Authors report their own experience in the beneficial effect of rFVIIa (NovoSeven, NovoNordisk, Denmark) administration in a patient with severe bleeding from the nasopharyngeal region after extensive fronto-basal injuries. After one dose of NovoSeven (2.4 mg - 40 microg/kg of body weight) reduction in bleeding, normalization of hemostasis parameters and hemodynamic stabilization of the patient were achieved.
Moskała
Marek
M
Klinika Neurotraumatologii, Collegium Medicum, Uniwersytet Jagielloński, Kraków.
Polak
Jarosław
J
Chruściel
Maciej
M
Fenikowski
Dariusz
D
D000328:Adult; D005151:Facial Injuries / Q000150:complications; D015942:Factor VIIa / Q000627:therapeutic use*; D006470:Hemorrhage / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D009302:Nasopharyngeal Diseases / Q000188:drug therapy* / Q000209:etiology; D012887:Skull Fractures / Q000150:complications
D015942:Factor VIIa